Stigma Resistance in Patients With Schizophrenia

Stigma Resistance in Patients With Schizophrenia (>> click to go to the journal's website) Schizophrenia Bulletin, 09/21/10

Sibitz I et al. – Stigma Resistance is a new and promising concept. The development of stigma–resisting beliefs might help individuals in their hope of finding a fulfilling life and in their recovery from mental illness. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Psychiatry >> Click here to see the complete list Examining the course and outcome of individuals diagnosed with schizophrenia and comorbid borderline personality disorder Schizophrenia Research, 10/07/10 Paternal age at birth of first child and risk of schizophrenia American Journal of Psychiatry, 10/20/10 Altered engagement of attention and default networks during target detection in schizophrenia Schizophrenia Research, 10/19/10

 

 

 

 

The Role of Religion in the Well-Being of Older Adults With Schizophrenia (>> click to go to the journal's website) Psychiatric Services, 09/08/10

Cohen CI et al. – Religiousness may have a favorable impact on the quality of life of older adults with schizophrenia, and it must be considered along with other therapeutically important agents. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Psychiatry >> Click here to see the complete list Examining the course and outcome of individuals diagnosed with schizophrenia and comorbid borderline personality disorder Schizophrenia Research, 10/07/10 Analysis of HapMap tag-SNPs in dysbindin (DTNBP1) reveals evidence of consistent association with schizophrenia European Psychiatry , 10/07/10 Suicidal attempts and increased right amygdala volume in schizophrenia Schizophrenia Research, 10/07/10

 

 

Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-analysis (>> click to go to the journal's website) British Journal of Psychiatry, 09/03/10

Singh SP et al. ?The goal of this sreview was to analyse the efficacy of add-on antidepressants for the treatment of negative symptoms of chronic schizophrenia. Antidepressants along with antipsychotics are more effective in treating the negative symptoms of schizophrenia than antipsychotics alone. Methods Systematic review and meta-analysis of randomised controlled trials comparing effect of antidepressants and placebo on negative symptoms of chronic schizophrenia, measured through standardised rating scales Outcome measured as standardised mean difference between end-of-trial and baseline scores of negative symptoms Results 23 trials from 22 publications (n = 819) Antidepressants involved selective serotonin reuptake inhibitors, mirtazapine, reboxetine, mianserin, trazodone and ritanserin; trials on other antidepressants not available Overall standardised mean difference moderate (?0.48) in favour of antidepressants and subgroup analysis revealed significant responses for fluoxetine, trazodone and ritanserin Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Psychiatry >> Click here to see the complete list Antidepressant use and colorectal cancer risk: A Danish population-based case control study British Journal of Cancer, 09/30/10 Bupropion for Depression in Schizophrenia Clinical Neuropharmacology, 10/01/10 Longitudinal Evidence for Unfavorable Effects of Antidepressants on Heart Rate Variability Biological Psychiatry, 09/21/10

 

Aripiprazole for late-life schizophrenia (>> click to go to the journal's website) Clinical Interventions in Aging, 09/01/10

Rado J et al. – Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating this situation are the high co–morbidity rates (both psychiatric and medical) in the elderly; age–related changes in pharmacokinetics leading to a heightened proclivity for adverse effects; and the potential for multiple, clinically relevant drug interactions. With this background in mind, the authors review diagnostic and treatment–related issues specific to elderly patients suffering from schizophrenia and other psychotic conditions, focusing on the potential role of aripiprazole. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Psychiatry >> Click here to see the complete list Neonatal vitamin D status and risk of schizophrenia: A population-based case-control study Archives of General Psychiatry, 09/10/10 Slow wave sleep deficits as a trait marker in patients with schizophrenia Schizophrenia Research, 09/29/10 Diagnostic and prognostic significance of Schneiderian first-rank symptoms: a 20-year longitudinal study of schizophrenia and bipolar disorder Comprehensive Psychiatry, 09/13/10

 

 

Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis (>> click to go to the journal's website) Journal of Evaluation in Clinical Practice, 07/28/10

Roussy JP et al. – Compared with olanzapine and quetiapine, ziprasidone produced savings to the health care system. Although ziprasidone generated incremental expenditures versus risperidone, it resulted in more QALYs. Based on this analysis, ziprasidone treatment possesses cost and therapeutic advantages compared with olanzapine and quetiapine. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Psychiatry >> Click here to see the complete list Neonatal vitamin D status and risk of schizophrenia: A population-based case-control study Archives of General Psychiatry, 09/10/10 Diagnostic and prognostic significance of Schneiderian first-rank symptoms: a 20-year longitudinal study of schizophrenia and bipolar disorder Comprehensive Psychiatry, 09/13/10 Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain Proceedings of the National Academy of Sciences of the United States of America, 09/09/10